Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05213637
Other study ID # EAL-HCC-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 25, 2018
Est. completion date April 30, 2023

Study information

Verified date February 2022
Source Chinese PLA General Hospital
Contact Shichun Lu, MD, PhD
Phone 86-10-66938209
Email Lsc620213@aliyun.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection.


Description:

HCC, accounting for 80% of all liver cancers, is the third most common cause of cancer-related death worldwide. Radical resection is considered as a curative strategy for patients with primary HCC. However, over 50% of patients experience recurrence after resection, resulting in a very low 5-year survival rate. EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood. This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL in preventing recurrence in patients with primary HCC at high recurrence risk after radical resection. Patients will be randomized in a 1:1 ratio to receive either 20 doses of EAL (1×10^9~2×10^10 per dose) infusion in combination of a single TACE or a single TACE only. Primary endpoint is the independent review committee-determined recurrence-free survival (from randomization to first recurrence or death from any cause). Secondary endpoints include overall survival, cancer-specific survival, adverse events and others.


Recruitment information / eligibility

Status Recruiting
Enrollment 430
Est. completion date April 30, 2023
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients with Stage Ia~IIIa primary HCC with high recurrence risk (defined as single tumor =5cm in diameter, or single tumor <5cm in diameter with MVI, PVTT, hepatic vein invasion, satellite lesions or AFP =400ng/mL, or multiple tumors). 2. Patients who have undergone a radical resection. 3. ECOG PS Score 0~2. 4. Child-Pugh Score = 7. 5. Patients with adequate hematologic and end-organ function. 6. HBV-HCC and HCV-HCC patients with active viral infection may receive antiviral treatment simultaneously. 7. Patients who have a life expectancy of at least 6 months. Exclusion Criteria: 1. Patients with a history of immune deficiency or autoimmune diseases (such as rheumatoid joint disease, systemic lupus erythematosus, vasculitis, multiple sclerosis, insulin-dependent diabetes mellitus, etc.). 2. Patients with a history of other malignant tumors in the past 5 years. 3. Patients who received chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, and hormone therapy within 1 month prior to screening. 4. Patients who have received microwave ablation, cryotherapy, high-power ultrasound focused ablation and other local ablation methods for liver tumors. 5. Patients with postoperative organ dysfunction or heart and lung diseases. 6. Patients allergic to albumin or with serious allergy history or mental disease. 7. Pregnant or lactating women. 8. Anticipated other clinical trials within 4 weeks before this trial. 9. Patients with HIV or Treponema pallidum infection, septicemia and other uncontrolled infection. 10. Patients after organ or bone marrow transplant. 11. Patients with drug or alcohol abuse/addiction. 12. Any condition that would, in the investigator's judgment, make it unsuitable for the donors to be enrolled.

Study Design


Intervention

Biological:
Expanded Activated Lymphocytes (EAL)
12~20 doses of EAL (1×10^9~2×10^10 cells per dose) will be infused into patients.
Procedure:
transarterial chemoembolization (TACE)
After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.

Locations

Country Name City State
China Chinese PLA General Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Chinese PLA General Hospital Immunotech Applied Science Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence-free survival (RFS) The time from randomization to first documented of disease recurrence determined by IRC or death from any cause (whichever occurs first). 6 years
Secondary Overall survival (OS) The time from randomization to death from any cause. 6 years
Secondary Cancer-specific survival (CSS) The time from randomization to death from HCC. 6 years
Secondary Adverse events (AE) Percentage of participants with adverse events. 6 years
See also
  Status Clinical Trial Phase
Completed NCT03007212 - Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Phase 4
Terminated NCT03236649 - The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects Phase 3
Withdrawn NCT04044326 - The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors N/A
Recruiting NCT04687969 - Multimodal Machine Learning Characterization of Solid Tumors
Completed NCT02562755 - Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Phase 3
Withdrawn NCT02406508 - Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Phase 2
Completed NCT01972672 - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT01247298 - A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma Phase 0
Completed NCT03735628 - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02188901 - Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study N/A
Active, not recruiting NCT04522908 - Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function Phase 2
Terminated NCT01433016 - Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI Phase 2
Withdrawn NCT04465734 - A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC Phase 3
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Active, not recruiting NCT03753659 - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Not yet recruiting NCT01821482 - A Study of DC-CIK to Treat Hepatocellular Carcinoma Phase 2
Completed NCT03516071 - A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC Phase 2
Completed NCT01761266 - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Phase 3
Completed NCT02794805 - Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis Phase 2